PURPOSE: Efflux transporters of the ATP-binding cassette (ABC) family are major determinants of chemoresistance in tumor cells. This study examined associations between functional variants in ABCB1, ABCC2 and ABCG2 genes and clinical outcomes in patients with epithelial ovarian/primary peritoneal cancer (EOC/PPC) followingplatinum and taxane-based chemotherapy. METHODS: Sequenom iPLEXTMGOLD Assay and MALDI-TOF platform were used to genotype the non-synonymous G2677T/A (rs2032582; encoding Ala893Ser/Thr) and synonymous C3435T (rs1045642; encoding Ile1145Ile) variants in ABCB1, the non-synonymous G1249A variant in ABCC2 (rs2273697; encoding Val417Ile), and the non-synonymous C421A variant in ABCG2 (rs2231142; encoding Q141K, Gln141Lys) in normal DNA from up to 511 women in Gynecologic Oncology Group (GOG) phase III trials, GOG-172 or GOG-182. Progression-free survival (PFS) and overall survival (OS) were analyzed in relation to genetic polymorphisms using Kaplan-Meier and Cox proportional hazards model. RESULTS: The C421A variant (CA+AA versus CC) in ABCG2 was associated with a 6-month longer median PFS (22.7 versus 16.8 months, p=0.041). In multivariate analysis, patients with variant genotypes were at a reduced risk of disease progression (hazard ratio [HR]=0.75, 95% confidence interval [CI]=0.59-0.96, p=0.022). The association between C421A and OS was not statistically significant (HR=0.88, 95% CI=0.67-1.15, p=0.356). None of the other variants measured in either ABCB1 or ABCC2 was associated with PFS or OS. CONCLUSION: The C421A variant in ABCG2, previously shown to be associated with enhanced protein degradation and drug sensitivity, was associated with longer PFS in advanced stage EOC/PPC patents treated with platinum+taxane-based chemotherapy. This finding requires further validation.
RCT Entities:
PURPOSE: Efflux transporters of the ATP-binding cassette (ABC) family are major determinants of chemoresistance in tumor cells. This study examined associations between functional variants in ABCB1, ABCC2 and ABCG2 genes and clinical outcomes in patients with epithelial ovarian/primary peritoneal cancer (EOC/PPC) following platinum and taxane-based chemotherapy. METHODS: Sequenom iPLEXTMGOLD Assay and MALDI-TOF platform were used to genotype the non-synonymous G2677T/A (rs2032582; encoding Ala893Ser/Thr) and synonymous C3435T (rs1045642; encoding Ile1145Ile) variants in ABCB1, the non-synonymous G1249A variant in ABCC2 (rs2273697; encoding Val417Ile), and the non-synonymous C421A variant in ABCG2 (rs2231142; encoding Q141K, Gln141Lys) in normal DNA from up to 511 women in Gynecologic Oncology Group (GOG) phase III trials, GOG-172 or GOG-182. Progression-free survival (PFS) and overall survival (OS) were analyzed in relation to genetic polymorphisms using Kaplan-Meier and Cox proportional hazards model. RESULTS: The C421A variant (CA+AA versus CC) in ABCG2 was associated with a 6-month longer median PFS (22.7 versus 16.8 months, p=0.041). In multivariate analysis, patients with variant genotypes were at a reduced risk of disease progression (hazard ratio [HR]=0.75, 95% confidence interval [CI]=0.59-0.96, p=0.022). The association between C421A and OS was not statistically significant (HR=0.88, 95% CI=0.67-1.15, p=0.356). None of the other variants measured in either ABCB1 or ABCC2 was associated with PFS or OS. CONCLUSION: The C421A variant in ABCG2, previously shown to be associated with enhanced protein degradation and drug sensitivity, was associated with longer PFS in advanced stage EOC/PPC patents treated with platinum+taxane-based chemotherapy. This finding requires further validation.
Authors: Tracy A Brooks; Hans Minderman; Kieran L O'Loughlin; Paula Pera; Iwao Ojima; Maria R Baer; Ralph J Bernacki; Tracy Brooks Journal: Mol Cancer Ther Date: 2003-11 Impact factor: 6.261
Authors: T Litman; M Brangi; E Hudson; P Fetsch; A Abati; D D Ross; K Miyake; J H Resau; S E Bates Journal: J Cell Sci Date: 2000-06 Impact factor: 5.285
Authors: Mike Mattie; Ashley Christensen; Mi Sook Chang; William Yeh; Suzanne Said; Yuriy Shostak; Linnette Capo; Alla Verlinsky; Zili An; Ingrid Joseph; Yi Zhang; Sathish Kumar-Ganesan; Karen Morrison; David Stover; Pia Challita-Eid Journal: Neoplasia Date: 2013-10 Impact factor: 5.715
Authors: Grace K Dy; Sumithra J Mandrekar; Garth D Nelson; Jeffrey P Meyers; Araba A Adjei; Helen J Ross; Rafat H Ansari; Alan P Lyss; Philip J Stella; Steven E Schild; Julian R Molina; Alex A Adjei Journal: J Thorac Oncol Date: 2013-01 Impact factor: 15.609
Authors: Marguerite L Palisoul; Jeanne M Quinn; Emily Schepers; Ian S Hagemann; Lei Guo; Kelsey Reger; Andrea R Hagemann; Carolyn K McCourt; Premal H Thaker; Matthew A Powell; David G Mutch; Katherine C Fuh Journal: Mol Cancer Ther Date: 2017-09-13 Impact factor: 6.261
Authors: Jerec W Ricci; Debbie M Lovato; Virginia Severns; Larry A Sklar; Richard S Larson Journal: Mol Cancer Ther Date: 2016-09-26 Impact factor: 6.261